Related Experiment Videos
Immunoradiotherapy for primary nonresectable hepatocellular carcinoma
1Johns Hopkins Hospital, Baltimore, Maryland.
The Surgical Clinics of North America
|April 1, 1989
Summary
Converting unresectable hepatoma (liver cancer) to resectable disease offers palliation and potential cure. Advances in radiolabeled immunoglobulin and multimodality treatments are expanding surgical options for more patients.
Area of Science:
- Hepatobiliary surgery
- Oncology
- Immunotherapy
Background:
- Hepatoma, or liver cancer, often presents as unresectable disease.
- Surgical resection is a primary curative treatment for liver cancer.
- Converting unresectable lesions to resectable ones improves patient outcomes.
Purpose of the Study:
- To highlight the significance of converting unresectable hepatoma to resectable disease.
- To discuss the role of novel therapies in expanding surgical candidacy for liver cancer patients.
Main Methods:
- Review of current treatment strategies for hepatoma.
- Analysis of the impact of radiolabeled immunoglobulin and multimodality treatments.
- Evaluation of patient selection for surgical resection.
Main Results:
- Conversion of unresectable hepatoma to resectable disease provides significant palliation.
- Emerging therapies are increasing the number of patients eligible for curative resection.
- Multimodality treatment approaches enhance the potential for successful surgical intervention.
Conclusions:
- Surgical resection remains a critical goal in hepatoma management.
- Advancements in targeted therapies are expanding the scope of surgical oncology for liver cancer.
- A multidisciplinary approach is key to optimizing treatment for unresectable hepatoma.